1. Home
  2. AOD vs MLYS Comparison

AOD vs MLYS Comparison

Compare AOD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AOD
  • MLYS
  • Stock Information
  • Founded
  • AOD 2006
  • MLYS 2019
  • Country
  • AOD United Kingdom
  • MLYS United States
  • Employees
  • AOD N/A
  • MLYS N/A
  • Industry
  • AOD Investment Managers
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AOD Finance
  • MLYS Health Care
  • Exchange
  • AOD Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • AOD 862.4M
  • MLYS 1.0B
  • IPO Year
  • AOD N/A
  • MLYS 2023
  • Fundamental
  • Price
  • AOD $8.51
  • MLYS $15.56
  • Analyst Decision
  • AOD
  • MLYS Strong Buy
  • Analyst Count
  • AOD 0
  • MLYS 3
  • Target Price
  • AOD N/A
  • MLYS $33.00
  • AVG Volume (30 Days)
  • AOD 498.7K
  • MLYS 866.7K
  • Earning Date
  • AOD 01-01-0001
  • MLYS 05-12-2025
  • Dividend Yield
  • AOD 12.85%
  • MLYS N/A
  • EPS Growth
  • AOD 213.63
  • MLYS N/A
  • EPS
  • AOD 1.93
  • MLYS N/A
  • Revenue
  • AOD $72,962,082.00
  • MLYS N/A
  • Revenue This Year
  • AOD N/A
  • MLYS N/A
  • Revenue Next Year
  • AOD N/A
  • MLYS N/A
  • P/E Ratio
  • AOD $4.41
  • MLYS N/A
  • Revenue Growth
  • AOD N/A
  • MLYS N/A
  • 52 Week Low
  • AOD $6.99
  • MLYS $8.24
  • 52 Week High
  • AOD $9.14
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • AOD 54.54
  • MLYS 55.06
  • Support Level
  • AOD $8.45
  • MLYS $14.75
  • Resistance Level
  • AOD $8.62
  • MLYS $16.11
  • Average True Range (ATR)
  • AOD 0.07
  • MLYS 0.90
  • MACD
  • AOD -0.01
  • MLYS -0.07
  • Stochastic Oscillator
  • AOD 42.21
  • MLYS 46.03

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: